# Cathy B Moelans

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 66 papers | 1,467 citations | 23 h-index | 36 g-index |
| 72 ext. papers | 1,700 ext. citations | 5.8 avg, IF | 4.54 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 66 | Analytical Validation of a Novel 6-Gene Signature for Prediction of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative, Early-Stage Breast Cancer.. *Clinical Chemistry*, **2022**, | 5.5 | 1 |
| 65 | Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 441-449 | 4 | 3 |
| 64 | The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis. *Cellular Oncology (Dordrecht)*, **2021**, 44, 1339-1349 | 7.2 | 0 |
| 63 | Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer. *Cancers*, **2021**, 13, | 6.6 | 1 |
| 62 | Methylation Profile of X-Chromosome-Related Genes in Male Breast Cancer. *Frontiers in Oncology*, **2020**, 10, 784 | 5.3 | 4 |
| 61 | The Physiological MicroRNA Landscape in Nipple Aspirate Fluid: Differences and Similarities with Breast Tissue, Breast Milk, Plasma and Serum. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 1 |
| 60 | Promoter hypermethylation in ductal carcinoma in situ of the male breast. *Endocrine-Related Cancer*, **2019**, 26, 575-584 | 5.7 | 5 |
| 59 | The molecular genetic make-up of male breast cancer. *Endocrine-Related Cancer*, **2019**, 26, 779-794 | 5.7 | 18 |
| 58 | Application of Nipple Aspirate Fluid miRNA Profiles for Early Breast Cancer Detection and Management. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 4 |
| 57 | Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. *Clinical and Experimental Metastasis*, **2019**, 36, 29-37 | 4.7 | 32 |
| 56 | Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. *Cancer Research*, **2018**, 78, 3112-3121 | 10.1 | 37 |
| 55 | Copy number profiling of oncogenes in ductal carcinoma of the male breast. *Endocrine-Related Cancer*, **2018**, 25, 173-184 | 5.7 | 4 |
| 54 | Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. *Journal of the National Cancer Institute*, **2018**, 110, 568-580 | 9.7 | 108 |
| 53 | Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification. *Journal of Clinical Pathology*, **2018**, 71, 351-359 | 3.9 | 8 |
| 52 | Differences in cancer gene copy number alterations between Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma. *Head and Neck*, **2018**, 40, 1986-1998 | 4.2 | 3 |
| 51 | Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. *Oncotarget*, **2018**, 9, 17078-17092 | 3.3 | 7 |
| 50 | Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis. *ELife*, **2018**, 7, | 8.9 | 24 |

| | | | |
|---|---|---|---|
| 49 | Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA). *Methods in Molecular Biology*, **2018**, 1708, 537-549 | 1.4 | 13 |
| 48 | Response to A. Matikas et al. *Journal of the National Cancer Institute*, **2018**, 110, 1282-1283 | 9.7 | |
| 47 | PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. *Targeted Oncology*, **2018**, 13, 769-777 | 5 | 6 |
| 46 | Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification. *Modern Pathology*, **2018**, 31, 1816-1833 | 9.8 | 3 |
| 45 | FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. *Molecular Oncology*, **2018**, 12, 1884-1894 | 7.9 | 11 |
| 44 | Optimal Fixation Conditions and DNA Extraction Methods for MLPA Analysis on FFPE Tissue-Derived DNA. *American Journal of Clinical Pathology*, **2017**, 147, 60-68 | 1.9 | 16 |
| 43 | A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity. *Journal of the National Cancer Institute*, **2017**, 109, | 9.7 | 16 |
| 42 | Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. *Oncotarget*, **2017**, 8, 55550-55561 | 3.3 | 10 |
| 41 | Progressive APOBEC3B mRNA expression in distant breast cancer metastases. *PLoS ONE*, **2017**, 12, e0171343 | 3.7 | 21 |
| 40 | Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study. *Oncotarget*, **2017**, 8, 3111-3123 | 3.3 | 20 |
| 39 | Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. *Modern Pathology*, **2016**, 29, 1460-1470 | 9.8 | 44 |
| 38 | DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. *Oncotarget*, **2016**, 7, 24778-91 | 3.3 | 20 |
| 37 | Promoter hypermethylation profiling of distant breast cancer metastases. *Breast Cancer Research and Treatment*, **2015**, 151, 41-55 | 4.4 | 11 |
| 36 | Methylation biomarkers for pleomorphic lobular breast cancer - a short report. *Cellular Oncology (Dordrecht)*, **2015**, 38, 397-405 | 7.2 | 10 |
| 35 | Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma. *Cancer Medicine*, **2015**, 4, 1525-35 | 4.8 | 32 |
| 34 | Chromosome 17 copy number changes in male breast cancer. *Cellular Oncology (Dordrecht)*, **2015**, 38, 237-45 | 7.2 | 9 |
| 33 | Promoter hypermethylation using 24-gene array in early head and neck cancer: better outcome in oral than in oropharyngeal cancer. *Epigenetics*, **2014**, 9, 1220-7 | 5.7 | 23 |
| 32 | Validation of DNA promoter hypermethylation biomarkers in breast cancer--a short report. *Cellular Oncology (Dordrecht)*, **2014**, 37, 297-303 | 7.2 | 29 |

| | | | |
|---|---|---|---|
| 31 | Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA. *Modern Pathology*, **2014**, 27, 869-74 | 9.8 | 19 |
| 30 | Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. *BMC Cancer*, **2014**, 14, 864 | 4.8 | 29 |
| 29 | CEP17 copy number increase does not indicate polysomy 17. *Journal of Clinical Pathology*, **2014**, 67, 454-5 | 3.9 | 7 |
| 28 | Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. *Cancer Letters*, **2014**, 344, 138-146 | 9.9 | 32 |
| 27 | Analysis of copy number changes on chromosome 16q in male breast cancer by multiplex ligation-dependent probe amplification. *Modern Pathology*, **2013**, 26, 1461-7 | 9.8 | 15 |
| 26 | Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. *PLoS ONE*, **2013**, 8, e82018 | 3.7 | 2 |
| 25 | ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous. *PLoS ONE*, **2013**, 8, e84189 | 3.7 | 13 |
| 24 | Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. *Breast Cancer Research*, **2012**, 14, R101 | 8.3 | 43 |
| 23 | Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. *Breast Cancer Research and Treatment*, **2012**, 135, 49-58 | 4.4 | 47 |
| 22 | Prognostic value of estrogen receptor and progesterone receptor conversion in distant breast cancer metastases. *Cancer*, **2012**, 118, 4929-35 | 6.4 | 72 |
| 21 | Formaldehyde substitute fixatives: effects on nucleic acid preservation. *Journal of Clinical Pathology*, **2011**, 64, 960-7 | 3.9 | 44 |
| 20 | Formaldehyde substitute fixatives. Analysis of macroscopy, morphologic analysis, and immunohistochemical analysis. *American Journal of Clinical Pathology*, **2011**, 136, 548-56 | 1.9 | 41 |
| 19 | Implications of rarity of chromosome 17 polysomy in breast cancer. *Lancet Oncology, The*, **2011**, 12, 1087-9 | 22.7 | 14 |
| 18 | Low frequency of HER2 amplification and overexpression in early onset gastric cancer. *Cellular Oncology (Dordrecht)*, **2011**, 34, 89-95 | 7.2 | 35 |
| 17 | Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. *Cellular Oncology (Dordrecht)*, **2011**, 34, 475-82 | 7.2 | 30 |
| 16 | ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. *Cellular Oncology (Dordrecht)*, **2011**, 34, 489-94 | 7.2 | 12 |
| 15 | Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. *Journal of Pathology*, **2011**, 225, 222-31 | 9.4 | 104 |
| 14 | Amplification testing in breast cancer by multiplex ligation-dependent probe amplification of microdissected tissue. *Methods in Molecular Biology*, **2011**, 755, 107-18 | 1.4 | 3 |

| | | | |
|---|---|---|---|
| 13 | Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. *Pathology Research International*, **2010**, 2011, 674182 | | 30 |
| 12 | Molecular Differences between Ductal CarcinomaIn Situand Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification Study. *Analytical Cellular Pathology*, **2010**, 33, 165-173 | 3.4 | 19 |
| 11 | ESR1 Amplification is Rare in Breast Cancer and is Associated with High Grade and High Proliferation: A Multiplex Ligation-Dependent Probe Amplification Study. *Analytical Cellular Pathology*, **2010**, 33, 13-18 | 3.4 | 15 |
| 10 | Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. *Modern Pathology*, **2010**, 23, 1029-39 | 9.8 | 78 |
| 9 | Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. *Modern Pathology*, **2010**, 23, 62-70 | 9.8 | 32 |
| 8 | ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. *Analytical Cellular Pathology*, **2010**, 33, 13-8 | 3.4 | 10 |
| 7 | Validation of a fully automated HER2 staining kit in breast cancer. *Cellular Oncology*, **2010**, 32, 149-55 | | 7 |
| 6 | Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. *Analytical Cellular Pathology*, **2010**, 33, 165-73 | 3.4 | 16 |
| 5 | Validation of a Fully Automated HER2 Staining Kit in Breast Cancer. *Analytical Cellular Pathology*, **2010**, 32, 149-155 | 3.4 | 1 |
| 4 | Multiplex Ligation-Dependent Probe Amplification to Detect HER2 Amplification in Breast Cancer: New Insights in Optimal Cut-Off Value. *Analytical Cellular Pathology*, **2010**, 32, 311-312 | 3.4 | 1 |
| 3 | HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection. *BMC Cancer*, **2009**, 9, 4 | 4.8 | 27 |
| 2 | HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. *Cellular Oncology*, **2009**, 31, 1-10 | | 22 |
| 1 | HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization. *Analytical Cellular Pathology*, **2009**, 31, 1-10 | 3.4 | |